Acumen completes enrollment of ALTITUDE-AD Phase 2 trial
Pharmaceuticals announced the completion of enrollment in its ALTITUDE-AD Phase 2 trial of sabirnetug in patients with early ...
Alzamend Neuro announces initiation date of Phase II trial of AL001
Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with ...
Porosome Therapeutics Unveils Groundbreaking Discovery in Alzheimer’s Disease Research and Treatment
Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced its latest development in identifying the secretory dysfunction responsible for Alzheimer’s Disease along with advancements in ...